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Introduction. Patients with β-thalassemia intermedia have a higher incidence of thromboembolic events compared to the general
population. Previous studies have shown that patients with sickle cell disease, who are also prone to ischemic events, have higher
intracranialarterialbloodﬂowvelocitiesmeasuredbytranscranialDopplersonography(TCD).Theaimofthisstudyistoevaluate
intracranial arterial ﬂow velocities in patients with β-thalassemia intermedia and compare the results with those found in healthy
subjects. Methods. Sixty-four patients with β-thalassemia intermedia and 30 healthy subjects underwent transcranial Doppler
sonography. Results. Signiﬁcantly higher ﬂow velocities were found in intracranial arteries of patients compared to controls (P =
0.001). Previously splenectomized patients with thrombocytosis showed higher ﬂow velocities than nonsplenectomized patients
without thrombosis. Conclusion. The increased ﬂow velocities in patients with β-thalassemia intermedia may point to a higher risk
of ischemic events. Preventive measures such as blood transfusion or antiplatelet treatment may be beneﬁcial in these patients.
1.Introduction
Patients with β-thalassemia intermedia (B-TI) seem to show
higher rates of thromboembolic events than individuals
without thalassemia or patients with β-thalassemia major,
in particular if they have been splenectomized [1]. It is
estimated that 4% of patients with β-thalassemia interme-
dia will experience a thromboembolic event [2]. Previous
splenectomy and thrombocytosis and/or platelet abnormali-
tiesaremajorfactorsassociatedwiththromboembolicevents
in patients with β-thalassemia intermedia [1, 3, 4], and
ischemic stroke is increasingly recognized as one of the most
devastating complications of this disease [5].
Ischemic stroke is also a known complication of sickle
cell disease [6]. In a prospective study in patients with this
condition, higher blood ﬂow velocity in the intracranial
arteries was associated with a higher risk of ischemic stroke
[7]. The stroke prevention trial in sickle cell anemia (STOP)
has indicated a role for transcranial Doppler sonography
(TCD) in measuring intracranial arterial ﬂow velocities to
identify sickle cell patients at a high risk of ischemic stroke
[8].TCDmeasurementofintracranialﬂowvelocitiesisofaid
in deciding when to start blood transfusion in these patients
to reduce the risk of ischemic stroke [8, 9].
An association between TCD ﬁndings and stroke risk
has been conﬁrmed in sickle cell disease; however, as far
as we know, no studies have been conducted to evaluate
TCD ﬁndings in patients with β-thalassemia intermedia,
another high-risk group for ischemic stroke. In the present
study, we compared the intracranial arterial ﬂow velocities




clinic aﬃliated with Shiraz University of Medical Sciences,
Southern Iran, for a period of one year during 2009.2 Anemia
Consecutive patients older than 15 years of age with con-
ﬁrmed β-thalassemia intermedia by complete blood count
and hemoglobin electrophoresis who were referred to an
outpatient thalassemia clinic enrolled in the study. Diagnosis
of B-TI was based on complete blood count, hemoglobin
electrophoresis, and initial hemoglobin (Hb) level of 7gr/dL,
and age of diagnosed anemia was after 2. All of them were
transfusion independent. Patients were recruited at a routine
follow-up visit with a hematologist in the clinic. Exclusion
criteria were a history of diabetes mellitus, hypertension,
ischemic heart disease, thrombosis, previous cerebrovascular
disease, sickle cell anemia, or inadequate temporal window
for TCD. The study was approved by the Ethics Commit-
tee of Shiraz University of Medical Sciences (no. 2885),
and written informed consent to participate was obtained
from all patients or their ﬁrst-degree families. All patients
were receiving folic acid (5mg/day) and hydroxyurea (8–
15mg/kg/day).
For each patient, we completed a data collection form
that included age, sex, place of residence, prior splenectomy,
prior transfusion, history of thrombosis, previous stroke
or transient ischemic attack, and laboratory information
(complete blood cell count, ferritin, blood urea nitrogen,
creatinine, alanine aminotransferase, aspartate aminotrans-
ferase, alkaline phosphatase, and albumin). Thrombocytosis
was deﬁned as a platelet count >500,000/dL.
Transcranial Doppler ultrasound was carried out in all
patients.AllTCDstudieswereperformedbyoneinvestigator
using a Legend TC22 transcranial Doppler ultrasound unit
(Bristol, UK) with a 2-MHz transducer. The two middle
cerebral arteries (MCAs), anterior cerebral arteries (ACAs),
posterior cerebral arteries (PCAs), and the terminal internal
carotid arteries were insonated using a temporal window
approach (Eleven patients had poor temporal window who
were excluded from the study). The basilar artery (BA)
and vertebral arteries were examined through a suboccipital
approach in sitting position. The highest mean ﬂow velocity
of each artery was recorded separately.
The control group consisted of 30 sex/age-matched sub-
jectswithnoknownhematologicdisease.Thesameexclusion
criteria as for the patients were used for the controls. All the
control subjects underwent TCD examination with the same
protocol.
The Mann-Whitney U test, Pearson correlation coeﬃ-
cient(r),andt-testwereusedforcomparisonofthevariables
between groups. Results are expressed as percentages and
absolute frequencies, where appropriate. Descriptive results
are presented as the mean ± standard deviation (SD).
P values <0.05 were considered signiﬁcant. Statistical anal-
yses were performed in SPSS version 15.0 (SPSS, Chicago, Ill,
USA).
3. Results
After applying the inclusion and exclusion criteria, 64
patients with β-thalassemia intermedia and 30 healthy
subjects were recruited. There were no signiﬁcant diﬀerences
between patients and controls according to sex (male: 40.6%
Table 1: Mean intracranial arterial ﬂow velocities in β-thalassemia





Left ICA 84.6 ±24.49 4 .1 ±20.7 0.097
Right ICA 83.1 ±25.68 6 .5 ±25.1 0.538
Left MCA 66.6 ±26.98 7 .9 ±23.9 0.001
Right MCA 71.3 ±28.28 5 .8 ±22.7 0.026
Left ACA 58.2 ±19.77 3 .4 ±18.3 0.002
Right ACA 57.3 ±19.06 9 .2 ±18.2 0.013
Left PCA 35.1 ±11.74 2 .1 ±11.6 0.021
Right PCA 34.8 ±10.84 1 .7 ±14.3 0.037
Left vertebral
artery 52.2 ±15.05 8 .3 ±14.5 0.102
Right vertebral
artery 55.6 ±15.36 2 .4 ±17.5 0.106
Basilar artery 66.1 ±17.27 6 .7 ±16.6 0.016
ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior
cerebral artery; PCA, posterior cerebral artery.
versus 53.3%; P = 0.251) or age (23.6±5.2v e r s u s2 5 .4±5.4;
P = 0.001). Mean velocities of all mentioned vessels were
measured in all patients and control subjects, and no missing
vessel was detected. Among the patients, 54.7% (35/64) had
undergone splenectomy, and 9.4% (6/64) had received a
bloodtransfusiononceortwiceayearbeforethestudy.None
of the control subjects had received transfusion. In patients,
mean Hb level was 9.3 ± 1.2g/dL (range 6.9–12.3), mean
white blood cell count was 8873 ± 2004/dL (range 4900–
13800),andmeanplateletcountwas523×103±219×103/dL
(range 188 × 103–1035 × 103). There were no signiﬁcant
diﬀerencesinage,whitebloodcellcount,orHblevelbetween
splenectomized and nonsplenectomized patients (P>0.05).
Mean platelet count was signiﬁcantly higher in patients who
had undergone splenectomy (696 × 103 ± 129 × 103/dL
versus 315 × 103 ± 78 × 103/dL; P = 0.001). All the
splenectomized patients had thrombocytosis, and none of
thenonsplenectomizedpatientshadthrombocytosis.Platelet
count correlated with blood ﬂow velocity in the right MCA
(r = 0.291, P = 0.020), left MCA (r = 0.366, P = 0.003),
left ACA (r = 0.258, P = 0.040), right PCA (r = 0.270,
P = 0.031), left PCA (r = 0.267, P = 0.033), and BA
(r = 0.300, P = 0.016). There were no correlations between
platelet count and blood ﬂow velocities of the other arteries
(P>0.05). Mean intracranial arterial ﬂow velocities in β-
thalassemiaintermediapatientswithorwithoutsplenectomy
are shown in Table 1. There were no signiﬁcant diﬀerences in
white blood cell count, Hb levels, or platelet count between
patients who had undergone transfusion and those who had
not (P>0.05).
Comparison of the mean intracranial artery ﬂow veloc-
ities between patients and controls showed signiﬁcantly
higher velocities in all intracranial arteries of patients (P =
0.001).Meanﬂowvelocitiesrecordedinpatientsandcontrols
are shown in Table 2.Anemia 3
Table 2: Mean intracranial arterial ﬂow velocities in β-thalassemia
intermedia patients and healthy controls.
Patients Healthy subjects P value
Left ICA 89.8 ±22.85 2 .1 ±8.6 0.001
Right ICA 84.9 ±21.75 0 .0 ±8.4 0.001
Left MCA 78.3 ±27.34 9 .4 ±9.1 0.001
Right MCA 79.3 ±26.24 8 .7 ±7.6 0.001
Left ACA 66.5 ±20.34 4 .4 ±9.5 0.001
Right ACA 63.8 ±19.44 2 .5 ±7.8 0.001
Left PCA 38.9 ±12.12 9 .7 ±6.6 0.001
Right PCA 38.6 ±13.22 7 .3 ±6.3 0.001
Left vertebral
artery 55.5 ±14.92 9 .5 ±4.6 0.001
Right vertebral
artery 59.3 ±16.82 9 .3 ±4.6 0.001
Basilar artery 71.9 ±17.64 7 .1 ±8.2 0.001
ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior
cerebral artery; PCA, posterior cerebral artery.
4. Discussion
In this study, higher blood ﬂow velocities were found in
all intracranial arteries of our patients. Flow velocity was
higher in most arteries of splenectomized patients compared
to nonsplenectomized patients, especially in the anterior
circulation. In addition, there was a correlation between
platelet count and ﬂow velocities.
Numerous studies in sickle cell anemia have evaluated
the role of TCD as a screening tool to identify and followup
patients at high risk of ischemic stroke [7–10]. TCD can
also detect asymptomatic cerebrovascular disease in patients
with sickle β-thalassemia [11], and the ﬁndings on TCD
study show a good correlation with cerebral angiography
[12]. However, no such studies have been performed in
β-thalassemia intermedia, another hematologic disease in
which there is a substantial associated risk of ischemic
stroke. Screening of asymptomatic β-thalassemia intermedia
patients by TCD has not been reported previously, and the
impact of this measure on further stroke remains to be
deﬁned. TI patients are prone to thromboembolic event,
especially those patients associated with splenectonomy and
thrombocytosis [2, 3].
There is growing evidence that increased intracranial
arterialﬂowvelocitiesassociatewithahigherriskofischemic
stroke [7, 13]. The recommendation for chronic red blood
cell transfusion in patients with high stroke risk is based on
ﬁndings from the STOP trial, in which patients with high
intracranial arterial ﬂow velocities showed a 90% reduction
in stroke rate following this treatment [8]. Patients with β-
thalassemia intermedia do not regularly receive blood trans-
fusion, and they have a higher risk of ischemic stroke than
β-thalassemia major patients, who are often treated with
transfusion[3].Inaddition,ahigherrateofthromboembolic
events occurs in splenectomized β-thalassemia intermedia
patients [3, 14], who usually have a higher platelet count.
The presence of a high ﬂow velocity in patients with β-
thalassemia intermedia may herald a cerebrovascular event
and indicate a need for special attention. The association of
ﬂow velocity with splenectomy and platelet count suggests
that these two factors should also be taken into account
when interpreting stroke risk in a patient with β-thalassemia
intermedia.
This study has some limitations. Patients were not
prospectively followedup to clarify the impact of higher
blood ﬂow velocities on the risk of ischemic stroke. The
interpretation presented here is based on previous studies,
mainly in sickle cell disease, which showed a higher risk of
stroke in association with higher ﬂow velocities measured by
TCD.Furthermore,wedidnotmeasureﬂowvelocitiesbefore
and after blood transfusion to estimate the impact of this
measure on reducing velocities.
In conclusion, in this ﬁrst study evaluating TCD ﬁndings
in β-thalassemia intermedia patients, higher intracranial
arterial blood ﬂow velocities were found in comparison
to normal subjects. These ﬁndings may indicate that
these patients are at a higher risk of ischemic events
and that preventive measures, such as blood transfusion
or antiplatelet drug administration, could be beneﬁcial.
Nonetheless, prospective randomized clinical trials would be
needed to establish recommendations in this regard.
Conﬂict of Interests
All the authors declare that they have no conﬂict of interests.
Acknowledgments
This study was ﬁnancially supported by Shiraz University of
Medical Sciences. They thank Shirin Parand at the Hematol-
ogy Research Center for help with paper preparation, and C.
Cavallo(authoraidintheEasternMediterranean)forediting
and improving the use of English in the paper. This paper is
relevant to the thesis of S. Emami with Project no. 2885.
References
[1] A. T. Taher, Z. K. Otrock, I. Uthman, and M. D. Cappellini,
“Thalassemia and hypercoagulability,” Blood Reviews, vol. 22,
no. 5, pp. 283–292, 2008.
[2] A. Taher, H. Isma’eel, G. Mehio et al., “Prevalence of throm-
boembolic events among 8,860 patients with thalassaemia
major and intermedia in the Mediterranean area and Iran,”
Thrombosis and Haemostasis, vol. 96, no. 4, pp. 488–491, 2006.
[3] M. D. Cappellini, L. Robbiolo, B. M. Bottasso, R. Coppola,
G. Fiorelli, and P. M. Mannucci, “Venous thromboembolism
andhypercoagulabilityinsplenectomizedpatientswiththalas-
saemia intermedia,” British Journal of Haematology, vol. 111,
no. 2, pp. 467–473, 2000.
[4] A. Tripodi, M. D. Cappellini, V. Chantarangkul et al., “Hyper-
coagulability in splenectomized thalassemic patients detected
by whole-blood thromboelastometry, but not by thrombin
generation in platelet-poor plasma,” Haematologica, vol. 94,
no. 11, pp. 1520–1527, 2009.4 Anemia
[5] M. Karimi, M. Khanlari, and E. A. Rachmilewitz, “Cere-
brovascular accident in β-thalassemia major (β-TM) and β-
thalassemia intermedia (β-TI),” American Journal of Hematol-
ogy, vol. 83, no. 1, pp. 77–79, 2008.
[6] K. Ohene-Frempong, S. J. Weiner, L. A. Sleeper et al.,
“Cerebrovascular accidents in sickle cell disease: rates and risk
factors,” Blood, vol. 91, no. 1, pp. 288–294, 1998.
[ 7 ]R .J .A d a m s ,V .C .M c K i e ,E .M .C a r le ta l . ,“ L o n g - t e r m
stroke risk in children with sickle cell disease screened with
transcranial Doppler,” Annals of Neurology,v o l .4 2 ,n o .5 ,p p .
699–704, 1997.
[8] M.T.Lee,S.Piomelli,S.Grangeretal.,“Strokepreventiontrial
in sickle cell anemia (STOP): extended follow-up and ﬁnal
results,” Blood, vol. 108, no. 3, pp. 847–852, 2006.
[9] N. Venketasubramanian, I. Prohovnik, A. Hurlet, J. P. Mohr,
and S. Piomelli, “Middle cerebral artery velocity changes
during transfusion in sickle cell anemia,” Stroke, vol. 25, no.
11, pp. 2153–2158, 1994.
[10] J. J. Seibert, C. M. Glasier, R. S. Kirby et al., “Transcranial
Doppler, MRA, and MRI as a screening examination for
cerebrovascular disease in patients with sickle cell anemia: an
8-year study,” Pediatric Radiology, vol. 28, no. 3, pp. 138–142,
1998.
[11] D. I. Zafeiriou, M. Prengler, N. Gombakis et al., “Central
nervoussystemabnormalitiesinasymptomaticyoungpatients
with Sβ-thalassemia,” Annals of Neurology,v o l .5 5 ,n o .6 ,p p .
835–839, 2004.
[12] R. J. Adams, F. T. Nichols, R. Figueroa, V. McKie, and T. Lott,
“Transcranial Doppler correlation with cerebral angiography
in sickle cell disease,” Stroke, vol. 23, no. 8, pp. 1073–1077,
1992.
[13] R. Adams, V. McKie, F. Nichols et al., “The use of transcranial
ultrasonography to predict stroke in sickle cell disease,” New
EnglandJournalofMedicine,vol.326,no.9,pp.605–610,1992.
[14] M. Karimi, H. Bagheri, F. Rastgu, and E. A. Rachmilewitz,
“Magnetic resonance imaging to determine the incidence of
brain ischaemia in patients with β-thalassaemia intermedia,”
Thrombosis and Haemostasis, vol. 103, no. 5, pp. 989–993,
2010.